The CDC now reports 180 suspected cases of unusual hepatitis in U.S. kids, an increase of 71 since their previous update, with adenovirus detected in about half of the cases; the percentage requiring liver transplants declined, however, from 15% to 9%, and no deaths have been reported since February.
Author: Praveen Suthrum
NEW YORK, May 19, 2022 /PRNewswire/ — Medscape Education will host nine educational symposia at Digestive Disease Week (DDW) 2022 in San Diego May 21- 24, estimated to reach 3,000 gastroenterology specialists attending the conference in person. The live symposia will address key topics in gastroenterology including inflammatory conditions and infectious diseases, such as ulcerative colitis, Helicobacter pylori infection, hepatobiliary carcinoma, Crohn’s disease, Clostridioides difficile, irritable bowel syndrome, and more.
When Lindsay S. learned she had inflammatory bowel disease at 24 years old, her first concern was how it might affect her plans to have a family and the potential impact on a child. “Even when I was first being put on medication, I wanted to know what effect it would have on future children,” she says. “I was coming up on childbearing years, so I wanted to know if I got pregnant what could those meds do to a baby. I was pretty picky about what meds I wanted to start with.”
May 17th, 2022 Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases.
Two abstracts include data generated in collaboration with Eli Lilly and Company and focusing on an AI-driven automated disease scoring technology aimed to accelerate clinical trials for ulcerative colitis A plenary session will feature the first publicly available data from the clinical registration study on SKOUT™, the company’s automated polyp detection algorithm in colonoscopy, representing results from the largest, US-based clinical trial evaluating AI in colorectal cancer screening conducted to date.
Researchers from ETH Zurich, University Hospital of Bern and the University of Bern have equipped gut bacteria with data logger functionality as a way of monitoring which genes are active in the bacteria. These microorganisms could one day offer a noninvasive means of diagnosing disease or assessing the impact of a diet on health.
LEXINGTON, Mass., May 18, 2022 (GLOBE NEWSWIRE) — FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, will host education advancement opportunities at the 2022 Digestive Disease Week (DDW®) annual conference and exhibition in booth 4343, held May 21-24 in San Diego. Fujifilm will host multiple physician-led, hands-on sessions within the booth, as well as an off-site symposium on the advances in endoluminal surgery and third space endoscopy.
Increasing transparency into such deals and how they affect quality is a step toward improving the system, a trade group says.
Incorporation and Use of APPs Ms. Enslin: Significant changes in healthcare delivery and a shift toward team-based care has expanded the role of APPs in GI practices. Drs. Weber and Vicari, recognizing that the role of the APP differs based on the needs of the GI practice, how are APPs used within each of your groups?
Abstract Background Epidemiological studies of incidence play an essential role in quantifying disease burden, resource planning, and informing public health policies. A variety of measures for estimating cancer incidence have been used. Appropriate reporting of incidence calculations is essential to enable clear interpretation. This review uses colorectal cancer (CRC) as an exemplar to summarize and describe variation in commonly employed incidence measures and evaluate the quality of reporting incidence methods.